Q BioMed Inc. (QBIO) financial statements (2020 and earlier)

Company profile

Business Address 366 MADISON AVE.
NEW YORK, NY 10017
State of Incorp. NV
Fiscal Year End November 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

11/30/2019
11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1732,6848252,39513113
Cash and cash equivalents1732,6848251,46913113
Other undisclosed cash, cash equivalents, and short-term investments   926  
Prepaid expense 133   
Other undisclosed current assets18  (926)  
Total current assets:1902,6978271,46913113
Noncurrent Assets
Intangible assets, net (including goodwill)450500293293231 
Intangible assets, net (excluding goodwill)450500293293231 
Other undisclosed noncurrent assets  (293)(293)(231) 
Total noncurrent assets:450500    
TOTAL ASSETS:6403,1978271,46913113
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,988392464498911
Accounts payable652    1
Accrued liabilities1,146  168  
Interest and dividends payable19030 49  
Other undisclosed accounts payable and accrued liabilities 36346428191 
Debt3,243  100296 
Due to related parties88871  
Other undisclosed current liabilities 30 2,612  
Total current liabilities:5,2384294713,2803871
Noncurrent Liabilities
Liabilities, other than long-term debt, including: 2,873 232  
Other undisclosed liabilities, other than long-term debt 2,873 232  
Other undisclosed noncurrent liabilities447     
Total noncurrent liabilities:4472,873 232  
Total liabilities:5,6863,3034713,5123871
Stockholders' equity
Stockholders' equity attributable to parent(5,045)(106)356(2,043)(256)11
Common stock201412993
Additional paid in capital37,32931,99423,1876,24986647
Accumulated deficit(42,394)(32,114)(22,843)(8,302)(1,130)(39)
Total stockholders' equity:(5,045)(106)356(2,043)(256)11
TOTAL LIABILITIES AND EQUITY:6403,1978271,46913113

Income statement (P&L) ($ in thousands)

11/30/2019
11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
Operating expenses(8,020)(9,020)(12,372)(6,347)(952)(38)
Other operating expense, net
(Other Expenses)
  (2,170)(825)(134) 
Operating loss:(8,020)(18,290)(29,083)(14,343)(1,087)(38)
Nonoperating expense
(Other Nonoperating expense)
(2,260)     
Interest and debt expense(1,460)(526)76(481)(21) 
Loss before gain (loss) on sale of properties:(11,740)(18,816)(29,007)(14,824)(1,108)(38)
Other undisclosed net income1,46019,80714,46515,92421 
Net income (loss):(10,280)990(14,542)1,100(1,087)(38)
Other undisclosed net loss attributable to parent (10,261) (8,272)  
Net loss attributable to parent:(10,280)(9,271)(14,542)(7,172)(1,087)(38)
Other undisclosed net income available to common stockholders, basic 23,77129,04214,372  
Net income (loss) available to common stockholders, diluted:(10,280)14,50014,5007,200(1,087)(38)

Comprehensive Income ($ in thousands)

11/30/2019
11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
Net income (loss):(10,280)990(14,542)1,100(1,087)(38)
Comprehensive income (loss), net of tax, attributable to parent:(10,280)990(14,542)1,100(1,087)(38)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: